443 related articles for article (PubMed ID: 35869032)
21. Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions.
Liu J; Zhang R; Xu ZP
Small; 2019 Aug; 15(32):e1900262. PubMed ID: 30908864
[TBL] [Abstract][Full Text] [Related]
22. Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: Improved pharmacokinetics, cell internalization and anticancer efficacy.
Hussain Z; Rahim MA; Jan N; Shah H; Rawas-Qalaji M; Khan S; Sohail M; Thu HE; Ramli NA; Sarfraz RM; Abourehab MAS
J Control Release; 2021 Jul; 335():130-157. PubMed ID: 34015400
[TBL] [Abstract][Full Text] [Related]
23. The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine.
O'Connell C; VandenHeuvel S; Kamat A; Raghavan S; Godin B
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077371
[TBL] [Abstract][Full Text] [Related]
24. Stimuli-Sheddable Nanomedicine Overcoming Pathophysiological Barriers for Potentiating Immunotherapy of Cancer.
Wang J; Zhou M; Chen F; Liu X; Gao J; Wang W; Wang H; Yu H
J Biomed Nanotechnol; 2021 Aug; 17(8):1486-1509. PubMed ID: 34544528
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy in rare ovarian cancer.
Laga T; Vergote I; Van Nieuwenhuysen E
Curr Opin Oncol; 2021 Sep; 33(5):447-456. PubMed ID: 34230441
[TBL] [Abstract][Full Text] [Related]
26. Nanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy.
Zhao YD; Muhetaerjiang M; An HW; Fang X; Zhao Y; Wang H
Biomaterials; 2021 Jan; 268():120552. PubMed ID: 33307365
[TBL] [Abstract][Full Text] [Related]
27. Polysaccharide-Based Stimulus-Responsive Nanomedicines for Combination Cancer Immunotherapy.
Li Q; Liu X; Yan C; Zhao B; Zhao Y; Yang L; Shi M; Yu H; Li X; Luo K
Small; 2023 Jun; 19(23):e2206211. PubMed ID: 36890780
[TBL] [Abstract][Full Text] [Related]
28. Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy.
Xiao M; Shi Y; Jiang S; Cao M; Chen W; Xu Y; Xu Z; Wang K
Front Oncol; 2022; 12():1039378. PubMed ID: 36523993
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
30. Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy.
Rajtak A; Ostrowska-Leśko M; Żak K; Tarkowski R; Kotarski J; Okła K
Front Immunol; 2022; 13():1018256. PubMed ID: 36439144
[TBL] [Abstract][Full Text] [Related]
31. Electromagnetic Nanomedicines for Combinational Cancer Immunotherapy.
Li J; Luo Y; Pu K
Angew Chem Int Ed Engl; 2021 Jun; 60(23):12682-12705. PubMed ID: 32671893
[TBL] [Abstract][Full Text] [Related]
32. The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.
Maiorano BA; Lorusso D; Maiorano MFP; Ciardiello D; Parrella P; Petracca A; Cormio G; Maiello E
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409229
[TBL] [Abstract][Full Text] [Related]
33. Nanotechnology for Boosting Cancer Immunotherapy and Remodeling Tumor Microenvironment: The Horizons in Cancer Treatment.
Gao S; Yang X; Xu J; Qiu N; Zhai G
ACS Nano; 2021 Aug; 15(8):12567-12603. PubMed ID: 34339170
[TBL] [Abstract][Full Text] [Related]
34. Nanomedicines as enhancers of tumor immunogenicity to augment cancer immunotherapy.
Dogheim GM; El Feel NE; Abd El-Maksod EA; Amer SS; El-Gizawy SA; Abd Elhamid AS; Elzoghby AO
Drug Discov Today; 2024 Mar; 29(3):103905. PubMed ID: 38295898
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive of N1-Methyladenosine Modifications Patterns and Immunological Characteristics in Ovarian Cancer.
Liu J; Chen C; Wang Y; Qian C; Wei J; Xing Y; Bai J
Front Immunol; 2021; 12():746647. PubMed ID: 34777359
[TBL] [Abstract][Full Text] [Related]
36. Multifunctional nanomedicines for synergistic photodynamic immunotherapy based on tumor immune microenvironment.
Guo R; Liu Y; Xu N; Ling G; Zhang P
Eur J Pharm Biopharm; 2022 Apr; 173():103-120. PubMed ID: 35283303
[TBL] [Abstract][Full Text] [Related]
37. Targeted delivery and enhanced uptake of chemo-photodynamic nanomedicine for melanoma treatment.
Huang X; Mu N; Ding Y; Lam HW; Yue L; Gao C; Chen T; Yuan Z; Wang R
Acta Biomater; 2022 Jul; 147():356-365. PubMed ID: 35577046
[TBL] [Abstract][Full Text] [Related]
38. Nanocatalysts for modulating antitumor immunity: fabrication, mechanisms and applications.
Wu X; Li Y; Wen M; Xie Y; Zeng K; Liu YN; Chen W; Zhao Y
Chem Soc Rev; 2024 Mar; 53(5):2643-2692. PubMed ID: 38314836
[TBL] [Abstract][Full Text] [Related]
39. Nanomedicine for T-Cell Mediated Immunotherapy.
Li F; Ouyang J; Chen Z; Zhou Z; Milon Essola J; Ali B; Wu X; Zhu M; Guo W; Liang XJ
Adv Mater; 2024 May; 36(22):e2301770. PubMed ID: 36964936
[TBL] [Abstract][Full Text] [Related]
40. Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy.
Cho Y; Milane L; Amiji MM
Expert Opin Biol Ther; 2019 Jun; 19(6):547-560. PubMed ID: 30933545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
